EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current advancements in cellular immunotherapy for autoimmune disease

Corbett T Berry, Caitlin S Frazee, Patrick J Herman, Sisi Chen, Anna Chen, Yvonne Kuo, Christoph T Ellebrecht

Seminars in Immunopathology · 2025

DOI: 10.1007/s00281-024-01034-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, 2025. Verfasst von Corbett T Berry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Autoimmune Diseases, Immunotherapy, Adoptive, Immunotherapy. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Penn Skin Biology and Diseases Resource-based Center, University of Pennsylvania, NIAMS NIH HHS, Penn Dermatology Skin of Color Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of autoimmune diseases is currently limited by therapies that largely suppress the immune system, often resulting in partial and temporary remissions. Cellular immunotherapies offer a targeted approach by redirecting immune cells to correct the underlying autoimmunity. This review explores the latest advances in cellular immunotherapies for autoimmune diseases, focusing on various strategies, such as the use of chimeric antigen receptor (CAR) T cells, chimeric auto-antibody receptor (CAAR) T cells, regulatory T cells (Tregs), and tolerogenic dendritic cells (TolDCs). We review recent preclinical studies and results from clinical trials that demonstrate the potential for these therapies to either deplete autoreactive cells or promote immune tolerance through broad or selective targeting of immune cell populations. Key challenges such as ensuring specificity, preventing off-target effects, and improving the longevity of therapeutic effects are discussed. The evolving landscape of cellular immunotherapies holds promise for more durable treatment responses and increased specificity for autoimmune disease treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesImmunotherapy, AdoptiveImmunotherapyHumansAnimalsDendritic CellsImmune ToleranceReceptors, Chimeric AntigenT-Lymphocytes, RegulatoryAutoimmunityT-Lymphocyte Subsets

Stichwörter der Autor:innen

AutoimmunityCellular immunotherapyChimeric antigen receptor T cells

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. chell@pennmedicine.upenn.edu.
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. chell@pennmedicine.upenn.edu.

Förderung

  • Penn Skin Biology and Diseases Resource-based Center, University of Pennsylvania
  • NIAMS NIH HHS
  • Penn Dermatology Skin of Color Fellowship
  • Colton Foundation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Berry, C. T., Frazee, C. S., Herman, P. J., Chen, S., Chen, A., Kuo, Y., & Ellebrecht, C. T. (2025). Current advancements in cellular immunotherapy for autoimmune disease. Seminars in Immunopathology. https://doi.org/10.1007/s00281-024-01034-5

Vancouver

Berry CT, Frazee CS, Herman PJ, Chen S, Chen A, Kuo Y, et al. Current advancements in cellular immunotherapy for autoimmune disease. Seminars in Immunopathology. 2025. doi:10.1007/s00281-024-01034-5

BibTeX
@article{Berry2025,
  author = {Berry, Corbett T and Frazee, Caitlin S and Herman, Patrick J and Chen, Sisi and Chen, Anna and Kuo, Yvonne and Ellebrecht, Christoph T},
  title = {Current advancements in cellular immunotherapy for autoimmune disease},
  journal = {Seminars in Immunopathology},
  year = {2025},
  doi = {10.1007/s00281-024-01034-5}
}
Kostenlos starten →